The global Digital Pathology Market is valued at USD 825.70 Million in 2022 and is projected to reach a value of USD 2164.20 Million by 2030 at a CAGR (Compound Annual Growth Rate) of 12.80% between 2023 and 2030.
Chronic and infectious diseases include cardiovascular, cancer, diabetes, influenza, orthopedic, and neurological conditions have become more prevalent worldwide, placing an increased load on healthcare systems and significantly affecting people's physical and mental wellbeing. For instance, according to a report by British Heart Foundation in January 2022, there were about 7.6 million persons in the UK who had heart disease as a result of cardiovascular illnesses (CVDs). The market is expanding as a result of the increased prevalence of cardiovascular illnesses and the growing demand for novel technologies that can diagnose these conditions.
Digital Pathology Market Size, 2022 To 2030 (USD Million)
- The quick sharing of whole slides to several pathologists is a feature of digital pathology platforms that allows them to instantly contribute to a case at once. For instance, Roche announced the introduction of CE-IVD's automated digital pathology algorithms, uPath HER2 (4B5) image analysis, and uPath HER2 Dual ISH image analysis for breast cancer to assist in determining the optimum treatment plan for each patient. This is accelerating market expansion as well.
- North America generated more than 41.3% of revenue share in 2022
- Asia Pacific is expected to grow at the quickest rate from 2023 to 2030
- Scanners segment accounted for the largest market growth. It contributed over 35.5% of the total revenue share in 2022
- Human Pathology segment revealed the most significant market growth, contributing more than 74.2% of the total revenue share in 2022
- Drug Discovery segment accounts for largest revenue of 30.2% in 2022
- Pharmaceutical & Biotechnology Companies will account for largest share of 34.8% in 2022
The has grown significantly. The rising incidence of chronic diseases—of which cancer alone affects millions of people worldwide—can be related to this strong increase. The use of digital pathology technologies has also shown the potential for up to 30% in cost reductions in pathology laboratory operations. Additionally, the incorporation of AI and machine learning in digital pathology is anticipated to considerably contribute to market expansion, with tools powered by AI reportedly assisting pathologists in making diagnoses up to 22% more accurately.
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
Top Market Trends
- Increasing demand for accuracy and precision in pathology: Better patient outcomes may result from pathologists using digital pathology to produce more precise and accurate diagnosis.
- Growing awareness of the benefits of digital pathology: The advantages of digital pathology, such as greater collaboration, increased efficiency, and decreased costs, are becoming more and more clear to pathologists and other healthcare practitioners.
- Technological advancements: Digital pathology is becoming more widely available and more reasonably priced due to technological developments like the creation of tools that are powered by artificial intelligence (AI).
- Increasing adoption of digital pathology in clinical practice: Diagnostic efficiency and accuracy are evolving as digital pathology is being used more frequently in clinical practice. Pathologists can improve accuracy and enable remote consultations and telepathology by analysing digital images of tissue samples on computer displays.
- Drug Discovery and Research Applications: Pharmaceutical and biotechnology firms were increasingly using digital pathology for biomarker discovery, preclinical and clinical research, and medication discovery. High-throughput image analysis and data management were made possible.
The globel Digital Pathology market can be categorized into Product, Type, Application, End User, Region. The Market can be categorized into Scanners, Software, Information management Software, Image Visualization & Analysis Software , Storage Systems based on Product. The Market can be categorized into Human Pathology, Veterinary Pathology based on Type. The Market can be categorized into Drug Discovery, Disease Diagnosis, Training & Education based on Application. The Market can be categorized into Pharmaceutical & Biotechnology Companies, Hospitals and Reference Laboratories , Academic & Research Institutes based on End User. The Market can be categorized into North America, Asia Pacific, Europe, Latin America, Middle East & Africa based on Region.
Below tree is interactive. You can click the nodes to get more information.
Based on Product
Scanners holds the largest share
The market is expected to be dominated by the scanners segment because they are essential instruments for transforming tissue slides into digital images that pathologists then examine using software for digital pathology. They are essential elements that have a significant impact on the precision and effectiveness of digital pathology workflows, and their rising sophistication and accessibility have sped up adoption across the globe in pathology labs.
Based on Type
Human Pathology will dominate the market during Forecast Period
The market is anticipated to be dominated by the human pathology segment due to the increasing prevalence of chronic diseases, particularly cancer, the demand for pathology services has increased. Digital pathology holds the potential of increased diagnostic accuracy and precision, which will improve patient outcomes.
Based on Application
Drug Discovery lead the market
Drug discover has dominated the market due to the growing need for novel medications and treatments, driven by the altering healthcare environment, is compatible with digital pathology's ability to speed up the process of drug discovery. It plays a crucial part in expediting research at every stage, from preclinical analysis to clinical trials. A further indication of digital pathology's vital role in expediting innovation and the creation of ground-breaking pharmaceutical solutions is the industry's growing embrace of it, which has made it the center of developments in drug discovery.
Based on End-user
Pharmaceutical & Biotechnology Companies will account for largest market share
In terms of end-users, pharmaceutical & biotechnology are anticipated to hold the greatest market share for because the global demand for cutting-edge medications and therapies is rising, and digital pathology's ability to speed up the drug discovery and development process. The importance of this technology in increasing research productivity, from early-stage drug screening to clinical trials, cannot be overstated.
Based on Region
North America will lead the market
North America is expected to dominate the market for because the region has a significant demand for advanced pathology services due to the large prevalence of chronic disorders, most notably cancer. Additionally, North America is a leader in accepting digital pathology solutions due to its propensity for early technological adoption. Government measures that are supportive, particularly those that promote telepathology and healthcare digitization, reinforce its leadership. Furthermore, North America is home to numerous industry giants, including Philips and Leica Biosystems, which help the continent maintain a dominant position in the rapidly changing field of digital pathology.
The constant interaction between well-established industry leaders and cutting-edge newcomers characterizes the competitive environment of the market. Industry leaders distinguishes out by providing a full range of digital pathology solutions, including scanners, software, and AI-driven analysis tools, to meet laboratory and healthcare needs. With its wide range of digital pathology products, such as whole slide scanners, image analysis software, and workflow automation solutions, Leica Biosystems, a Danaher subsidiary, has a sizable market share. Technological advancement, the incorporation of AI, and the pursuit of improved diagnostic accuracy in healthcare continue to alter the changing landscape.
The players in the global market include Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (US), Glencoe Software (US), Konfoong biotech international co. ltd. (China), Inspirata Inc. (US), PathAI (US), Proscia Inc. (US), Kanteron Systems (Spain), Mikroscan Technologies (US), Motic (US), Paige (US) among others.
Recent Market Developments
- June 2022: The VENTANA DP 600 slide scanner for digital pathology was introduced by F. Hoffmann-LA Roche Itd., improving patient care through accurate diagnosis.
- September 2022: Maintaining file compatibility between the Leica Biosystems Aperio GT 450 series of scanners and the Indica Labs Halo range of software solutions allowed Danaher Corporation and Indica Labs to collaborate on the delivery of compatible digital pathology workflow solutions.
- 2022: The NanoZoomer S360MD Slide scanner system from Hamamatsu has been given US FDA 510(k) clearance for primary diagnostic use.
Segmentation of the Global Market
- Product (Scanners, Software, Information management Software, Image Visualization & Analysis Software , Storage Systems )
- Type (Human Pathology, Veterinary Pathology)
- Application (Drug Discovery, Disease Diagnosis, Training & Education)
- End User (Pharmaceutical & Biotechnology Companies, Hospitals and Reference Laboratories , Academic & Research Institutes)
- Region (North America, Asia Pacific, Europe, Latin America, Middle East & Africa)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Leica Biosystems (US)
- Koninklijke Philips N.V. (Netherlands)
- Hamamatsu Photonics (Japan)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- 3DHISTECH (Hungary)
- Apollo Enterprise Imaging (US)
- XIFIN Inc. (US)
- Huron Digital Pathology (Canada)
- Visiopharm A/S (Denmark)
- Aiforia Technologies Oy (Finland)
- Akoya Biosciences (US)
- Corista (US)
- Indica Labs (US)
- Objective Pathology Services (Canada)
- Sectra AB (Sweden)
- OptraSCAN (US)
- Glencoe Software (US)
- Konfoong biotech international co. ltd. (China)
- Inspirata Inc. (US)
- PathAI (US)
- Proscia Inc. (US)
- Kanteron Systems (Spain)
- Mikroscan Technologies (US)
- Motic (US)
- Paige (US)
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options